

#### **FACSIMILE COVER SHEET**

#### **SALIWANCHIK, LLOYD & SALIWANCHIK**

A Professional Association 2421 N.W. 41<sup>st</sup> Street Suite A-1 Gainesville, FL 32606

Telephone (352) 375-8100 Facsimile (352) 372-5800

TO:

Group Art Unit 1645

FROM:

Frank C. Eisenschenk, Ph.D.

**COMPANY:** 

U.S. Patent & Trademark Office

DATE:

April 1, 2002

**FAX NO.:** 

1-703-872-9306

NO. OF PAGES: 6

(INCLUDING COVER SHEET)

#### SUBJECT/MESSAGE:

U.S. Patent Application Docket No. GEN-100D1

HUMAN DEFENSIN DEF-X (Bougueleret, Chumakov)

Serial No. 10/045,180; Filed October 18, 2001

Your Ref.: 30.US2.DIV

# THIS IS AN OFFICIAL DOCUMENT. PLEASE DELIVER IMMEDIATELY.

Attachments: Information Disclosure Statement PTO/SB/08 (3 pages)

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

TRANSACTION REPORT

APR-01-2002 MON 04:04 PM

FOR: SALIWANCHIK, LLOYD&SALIWA

352 372 5800

DATE START RECEIVER	TX TIME	PAGES TYPE	NOTE	M# DP
APR-01 04:01 PM 1703872930	6 3′ 10″	6 SEND	OK	158

TOTAL:

3M 10S PAGES:

6

#### **FACSIMILE COVER SHEET**

### SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association 2421 N.W. 41<sup>st</sup> Street Suite A-1 Gainesville, FL 32606

Telephone (352) 375-8100 Facsimile (352) 372-5800

TO:

**Group Art Unit 1645** 

FROM:

Frank C. Eisenschenk, Ph.D.

**COMPANY:** 

U.S. Patent & Trademark Office

DATE:

April 1, 2002

**FAX NO.:** 

1-703-872-9306

NO. OF PAGES: 6

(INCLUDING COVER SHEET)

#### SUBJECT/MESSAGE:

U.S. Patent Application Docket No. GEN-100D1

HUMAN DEFENSIN DEF-X (Bougueleret, Chumakov)

Serial No. 10/045,180; Filed October 18, 2001

Your Ref.: 30.US2.DIV

THIS IS AN OFFICIAL DOCUMENT.



MAY 1 8 2004 that this correspondence is being

and Trademark Office on April 1, 2002.



INFORMATION DISCLOSURE STATEMENT

Examining Group 1645

Patent Application

Docket No. GEN-100D1

Serial No. 10/045,180

Frank C. Eisenschenk, Ph.D., Patent Attorney

facsimile transmitted to the United States Patent

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

(Unassigned)

Art Unit

1645

Applicant(s)

Lydie Bougueleret and Ilya Chumakov

Serial No.

10/045,180

Filed

October 18, 2001

For

HUMAN DEFENSIN POLYPEPTIDE DEF-X, GENOMIC DNA AND CDNA,

COMPOSITION CONTAINING THEM AND APPLICATIONS TO DIAGNOSIS AND

TO THERAPEUTIC TREATMENT.

Assistant Commissioner for Patents Washington, D.C. 20231

# INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R §§ 1.97 and 1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent application:

U.S. Serial No. 09/486,580, filed February 25, 2000.

37 C.F.R. § 1.98(d) states that a copy of any patent, publication, or other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the Office in a prior application, provided that the prior application is properly identified in the statement and relied on for an earlier filing date under 35 U.S.C. § 120.

As copies of the references cited on the attached form PTO-1449, can be found in patent application Serial Number 09/486,580, filed February 25, 2000, copies of those references are not provided herewith. The subject application, Serial No. 10/045,180, claims the benefit under 35 U.S.C. § 120 of the filing date of patent application Serial No. 09/486,580. Accordingly, Applicants respectfully request that the copies of references supplied in the Information Disclosure Statement of the 09/486,580 application, as well as references cited during prosecution thereof, be made of record in this application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100 Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik

A Professional Association 2421 N.W. 41<sup>st</sup> Street, Suite A-1 Gainesville, FL 32606-6669

FCE/an

Attachment: PTO Form SB/08A (Substitute for Form 1449)

MAY 1 0 2004

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449A/PTO		Con	nplete if Known		
			IDE	Application Number	10/045,180
INFORMATION DISCLOSURE				Filing Date	October 18, 2001
SIAIEW	STATEMENT BY APPLICANT  (use as many sheets as necessary)			First Named Inventor	Lydie Bougueleret
(L				Art Unit	1645
		Examiner Name	Unassigned		
Sheet	1	of	3 ′	Attorney Docket Number	GEN-100D1

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	U1	US- 5,242,902	09-07-1993	Murphy et al.	All		
	U2	US- 5,641,497	06-24-1997	Bevins et al.	All		
	U3	US-					
	U4	US-					
	U5	US-					
	U6	US-					
	U7	US-					
	U8 .	US-					
	U9	US-					
	U10	US-					
	U11	US-					
	U12	US-					
	U13	US-					
	U14	US-					
	U15	US-					
	U16	UŞ-					
	U17	US-					
	U18	US-					
	U19	US-					
	U20	US-		<u> </u>			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1 -	WO 89/11291	11-30-1989	Invitron Corp.	All	
	F2	, WO 94/21672	09-29-1994	Regents of U. of Calif.	All	Π
	F3	WO 95/32287	11-30-1995	Magainin Pharmaceuticals	All	
	F4					
	F5					
	F6			<u> </u>		
	F7					
	F8					Г
	F9					
	F10					

	<u> </u>
Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

1645

10/045,180

October 18, 2001

Lydie Bougueleret

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Application Number** 

**First Named Inventor** 

**Filing Date** 

**Group Art Unit** 

Substitute for form 1449B/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Examiner Name** Unassigned Sheet of **Attorney Docket Number GEN-100D1** 3

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, joumal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	R1	BEVINS, et al. [1996] "Human Enteric Defensin Genes: Chomosomal Map Position and a Model for Possible Evolutionary Relationship", <i>Genomics</i> , 31:95-106	
	R2	GANZ et al. [1994] "Defensins", Current Opinion in Immunology, 6:584-589	
	R3	GANZ et al. [1995] "Defensins", <i>Pharmac Ther.</i> , 66:191-205	
	R4	HUGHES, A. [1999] "Evolutionary Diversification of the Mammalian Defensins", CMLS, Cell. Mol. Life Sci. 56:94-103	
	R5	HUGHES, A. et al. [1997] "Coordinated Amino Acid Changes in the Evolution of Mammalian Defensins", J. Mol. Evol. 44:675-82	
,	R6	KAGAN et al. [1994] "Defensins: a Family of Antimicrobial and Cytotoxic Peptides", Toxicology, 87:131-149	
	R7	LEHRER et al. [1992] "Defensins: Endogenous Antibiotic Peptides from Human Leukocytes", Ciba Foundation Symposium 171:276-293	
	R8	LERNER R. [1982] "Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity", Nature 299:592-96	
	R9	MALLOW et al. [1996] "Human Enteric Defensins", The Journal of Biological Chemistry 271:4038-4045	
	R10	MARTIN et al. [1995] "Defensins and Other Endogenous Peptide Antibiotics of Vertebrates", <i>Journal of Leukocyte Biology</i> 58:128-136	
	R11	RAJ, P. [2000] "Large-scale Synthesis and Functional Elements for the Antimicrobial Activity of Defensins", Biochem. J. 347:633-41	
	R12	SPARKES et al. [1989] "Assignment of Defensin Gene(s) to Human Chromosome 8p23", Genomics 5:240-244	
	R13	WHITE et al. [1995] "Structure, Function, and Membrane Integration of Defensins", Current Option in Structural Biology 5:521-527	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

MAY 1 2004

MAY 1 0 2004

Under the serwork Reduction Act 8 need to person control number.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO

Sheet

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


3 of 3

Complete if Known				
Application Number	10/045,180			
Filing Date	October 18, 2001			
First Named Inventor	Lydie Bougueleret			
Group Art Unit	1645			
Examiner Name	Unassigned			
Attorney Docket Number	GEN-100D1			

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	R14	WILDE et al. [1989] "Purification and Characterization of Human Neutrophil Peptide 4, a Novel Member of the Defensin Family", <i>Journal of Biological Chemistry</i> 264 (19):11200-11203				
	R15					
	R16					
	R17					
	R18					
	R19					
-	R20					
	R21					
	R22					
	R23		ļ			
	R24					
	R25					
	R26		:			

Examiner	Date	
Signature	Considered	

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.